On October 26, 2020 Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL) therapeutic platform, reported three upcoming poster presentations discussing INTASYL compounds, including posters being delivered by two development partners, AgonOx, Inc. and the Helmholtz Zentrum München, at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) (SITC 2020), to be held virtually from November 9-14, 2020 (Press release, Phio Pharmaceuticals, OCT 26, 2020, View Source [SID1234569042]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Photo – View Source
Poster details are as follows:
Poster Sponsor:
Phio Pharmaceuticals
Title:
Combination intratumoral treatment with INTASYL self-delivering RNAi
targeting TIGIT and PD-1/PD-L1 improves tumor control compared to
monotherapy in a CT26 model of murine colorectal cancer
Authors:
Benjamin Cuiffo, et al.
Abstract Number:
198
Poster Sponsor:
AgonOx, Inc.
Title:
Increasing activation of human tumor-reactive T cells (CD39+CD103+CD8+) by
gene silencing of PD1 with self-delivering RNAi INTASYLTM
Authors:
Colin J. Thalhofer, et al.
Abstract Number:
172
Poster Sponsor:
Helmholtz Zentrum München
Title:
New checkpoints controlling function of cytotoxic lymphocytes infiltrating human carcinoma
Authors:
Anna Herbstritt, et al.
Abstract Number:
599
An archived version of the Phio presentation will be made available on the "Investors – Events and Presentations" section of the Company’s website (click here).